PD-L1 expression at the tumour–stromal interface resulted in a better outcome, specifically, an improvement of ORRs (37.5% versus 8.3%), PFS (6.5 versus 1.3 months), and median OS (12.8 versus 7.6 months) [11] (Table 1). The gene discussed is CD274; the disease is neoplasm.